Propanc Biopharma Inc (PPCB)

[swamp-rat]

On February 20, 2018, Propanc Biopharma, Inc. (the “Company”) announced that it received an allowance from the European Patent Office on a key patent application for a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union. The allowed patent application is the first approval for the Company in the European Union, which protects the Company’s lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.